Idioma:

The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism

Carmena, R. ; Roederer, G. ; Mailloux, H. ; Lussier-Cacan, S. ; Davignon, J.

Metabolism, clinical and experimental, 1993-07, Vol.42 (7), p.895-901 [Periódico revisado por pares]

New York, NY: Elsevier Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism
Autor: Carmena, R. ; Roederer, G. ; Mailloux, H. ; Lussier-Cacan, S. ; Davignon, J.
Assuntos: Adult ; ALLELES ; Apolipoproteins E - genetics ; BIOCHEMICAL POLYMORPHISM ; Biological and medical sciences ; CHOLESTEROL ; COLESTEROL ; DRUG THERAPY ; FAMILIA ; FAMILIAL INCIDENCE ; FAMILIES ; FAMILLE ; Female ; FENOTIPOS ; GENE ; General and cellular metabolism. Vitamins ; GENES ; Heterozygote ; Humans ; Hyperlipoproteinemia Type II - blood ; Hyperlipoproteinemia Type II - drug therapy ; Hyperlipoproteinemia Type II - genetics ; Lipids - blood ; LIPOPROTEINAS ; LIPOPROTEINE ; LIPOPROTEINS ; Lovastatin - therapeutic use ; Male ; Medical sciences ; METABOLIC DISORDERS ; Middle Aged ; Pharmacology. Drug treatments ; PHENOTYPE ; PHENOTYPES ; POLIMORFISMO BIOQUIMICO ; Polymorphism, Genetic ; POLYMORPHISME BIOCHIMIQUE ; Receptors, LDL - genetics ; Retrospective Studies ; TERAPEUTICA MEDICAMENTOSA ; THERAPEUTIQUE MEDICAMENTEUSE ; TRASTORNOS METABOLICOS ; TROUBLE DU METABOLISME
É parte de: Metabolism, clinical and experimental, 1993-07, Vol.42 (7), p.895-901
Notas: 9420808
S30
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: In a retrospective study, we examined the influence of apolipoprotein (apo) E polymorphism and gender on the response to treatment with 80 mg/d lovastatin in a homogeneous population of patients with familial hypercholesterolemia (FH), most of whom were carriers of the 10-kb deletion of the low-density lipoprotein (LDL) receptor gene. Apo E phenotype distribution among the 189 FH patients was not different from that of a normal population sample. The total and LDL cholesterol (LDL-C) response to lovastatin in the overall group (men and women) was significantly lower in the E4 subset compared with E2 and E3 subsets. This finding is in agreement with trends observed in previous reports. On the other hand, the response of LDL-C to lovastatin was significantly lower in E4 men than in E4 women, whereas the high-density lipoprotein cholesterol (HDL-C) concentration in the E4 group increased significantly more in men than in women, suggesting a role of gender in modulating the response to lovastatin. Hence, apo E polymorphism influenced LDL-C (and HDL-C) response to lovastatin in men, but not in women, revealing the existence of a gene-by-gender interaction. These findings were independent of the nature of the LDL receptor defect. We conclude that male FH patients carrying the ϵ4 allele respond less efficiently to lovastatin than men carrying the ϵ3 or ϵ2 allele or women of any apo E phenotype with respect to decreasing total cholesterol and LDL-C levels, but respond more efficiently with respect to increasing HDL-C levels. The full practical implication of these findings remains to be explored.
Editor: New York, NY: Elsevier Inc
Idioma: Inglês

Links

Voltar para lista de resultados

Anterior Resultado 7 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism

Carmena, R. ; Roederer, G. ; Mailloux, H. ; Lussier-Cacan, S. ; Davignon, J.

New York, NY: Elsevier Inc

Buscando em bases de dados remotas. Favor aguardar.